Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - linezolid - solution for infusion - linezolid 2 mg / 1 ml - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected.linezolid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as:1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

1 polypropylene bag (300 ml) -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

propharma medical supplies greece - 1 polypropylene bag (300 ml) - infusion - 2mg/ml - infections-antibacterial

Singapore - English - HSA (Health Sciences Authority)

goldplus universal pte ltd - linezolid - infusion, solution - linezolid 2 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: silicon dioxide; sodium stearylfumarate; copovidone; mannitol; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: mannitol; silicon dioxide; copovidone; sodium stearylfumarate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; copovidone; mannitol; silicon dioxide; sodium stearylfumarate; titanium dioxide; hypromellose; macrogol 400 - akm linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,akm linezolid is active against gram-positive bacteria only. akm linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.